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Abstract
Tumor-associated macrophages (TAMs) enhance tumor growth in mice and are correlated with a worse
prognosis for breast cancer patients. While early therapies sought to deplete all macrophages, current
therapeutics aim to reprogram pro-tumor macrophages (M2) and preserve those necessary for
anti-tumor immune responses (M1). Recent studies have shown that c-MYC (MYC) is induced in M2
macrophages in vitro and in vivo where it regulates the expression of tumor-promoting genes. In a myeloid
lineage MYC KO mouse model, MYC had important roles in macrophage maturation and function leading
to reduced tumor growth. We therefore hypothesized that targeted delivery of a MYC inhibitor to
established M2 TAMs could reduce polarization toward an M2 phenotype in breast cancer models.
Methods: In this study, we developed a MYC inhibitor prodrug (MI3-PD) for encapsulation within
perfluorocarbon nanoparticles, which can deliver drugs directly to the cytosol of the target cell through
a phagocytosis independent mechanism. We have previously shown that M2-like TAMs express
significant levels of the vitronectin receptor, integrin β3, and in vivo targeting and therapeutic potential
was evaluated using αvβ3 integrin targeted rhodamine-labeled nanoparticles (NP) or integrin
αvβ3-MI3-PD nanoparticles.
Results: We observed that rhodamine, delivered by αvβ3-rhodamine NP, was incorporated into M2
tumor promoting macrophages through both phagocytosis-independent and dependent mechanisms,
while NP uptake in tumor suppressing M1 macrophages was almost exclusively through phagocytosis. In
a mouse model of breast cancer (4T1-GFP-FL), M2-like TAMs were significantly reduced with
αvβ3-MI3-PD NP treatment. To validate this effect was independent of drug delivery to tumor cells and
was specific to the MYC inhibitor, mice with integrin β3 knock out tumors (PyMT-Bo1 β3KO) were
treated with αvβ3-NP or αvβ3-MI3-PD NP. M2 macrophages were significantly reduced with
αvβ3-MI3-PD nanoparticle therapy but not αvβ3-NP treatment.
Conclusion: These data suggest αvβ3-NP-mediated drug delivery of a c-MYC inhibitor can reduce
protumor M2-like macrophages while preserving antitumor M1-like macrophages in breast cancer.
Key words: MYC, β3 integrin, nanoparticles, breast cancer, macrophages, drug delivery
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Introduction
New breast cancer therapies have significantly
improved patient outcomes over the last decade, but
for some subtypes or advanced malignancies, there
are limited therapeutic options. Immunotherapies
have primarily focused on enhanced T cell activation
and increased cytotoxicity towards cancer cells.
However, many breast cancers have high numbers of
tumor-associated macrophages (TAMs) which, in
addition to promoting tumor growth, repress
antitumor T cell responses, correlate with poor
prognosis, and limit the efficacy of immunotherapy
[1, 2]. Previous work has shown that macrophage
depletion reduces tumor size in breast and other
cancers [3].
Tumor-associated macrophages encompass a
spectrum of subtypes with diverse functions, but are
commonly divided into two broad categories:
classically polarized M1 phenotype (antitumor)
macrophages and alternatively polarized M2
phenotype (protumor) macrophages. Inherently
cleared by the macrophage monocyte phagocytic
system (MPS), nanoparticle technologies have been
used as macrophage imaging agents (SPIO NP) [4, 5]
and therapeutics [6-9]. Iron oxide nanoparticles have
been a dominant component in many of these
nanosystems due to their ability to influence
macrophages toward an M1 phenotype, increase
M1/M2 ratios, and promote anti-tumor immune
responses [10, 11]. Examples of iron oxide containing
nanoparticles that repolarize macrophages include ex
vivo hyaluronic acid decorated SPIO NP (HIONs) [12]
and immune stimulatory formulations; TLR3 agonist
poly (I:C) [13], melanin-like iron oxide NP
(Fe@PDA-PEG) [14], photogeneration of reactive
oxygen species [15] and iron oxide nanoparticles
under AMF exposure [16-18]. Encapsulation of
therapeutic cargo that inhibits proteins or genes
specific to M2 macrophages or TAM-suppressive
functions can further improve specificity [19].
In myeloid cells, the b-HLHZIP transcription
factor c-MYC (MYC) has been shown to regulate
macrophage inflammatory responses, macrophage
maturation and M2 polarization, and tumorpromoting functions [20, 21]. Therapeutic targeting of
MYC in TAMs could therefore reduce the ability of
macrophages to polarize to an immune suppressive
M2 phenotype and enhance the switch to an
inflammatory response. Previous attempts at
inhibiting MYC function have included anti-sense
nucleic acid strategies [22], RNA interference [23], and
interference with MYC-MAX dimerization and
subsequent E-box binding using small molecules
[24-32]. Several small-molecule inhibitors of the
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MYC-MAX interaction have been reported [24, 33-36]
but all were challenged by rapid metabolism and poor
bioavailability, leading to poor anti-tumor responses.
To overcome these barriers, we used a potent small
molecule inhibitor that we designed into a lipaselabile phosphatidylcholine prodrug, which enables
stable incorporation into the phospholipid membrane
of targeted perfluorocarbon nanoparticles [37] (See
Supplemental Data).
For the present experimental work, we designed
a
MYC
inhibitor
prodrug
(MI3-PD)
for
perfluorocarbon nanoparticle delivery to M2
macrophages through activated integrin αvβ3 with
the intent to disrupt M2 polarization without
compromising macrophage viability. We found that
human breast cancer patient tumors have increased
numbers of integrin αvβ3-positive macrophages, and
we provide new evidence that human breast cancer
TAMs express MYC. We also show that αvβ3-targeted
nanoparticles at least in part, are taken up by a
phagocytosis-independent
mechanism
in
M2
macrophages. In murine immunocompetent models
of estrogen receptor positive (ER+) and triplenegative breast cancers, αvβ3-targeted MI3 prodrug
nanoparticles (αvβ3-MI3-PD NP) decreased M2
polarized TAMs in mammary fat pad tumors and
preserved M1 TAM numbers. These data provide
therapeutic proof of principle that inhibition of MYC
signaling through αvβ3-targeted drug delivery of the
small molecule MI3-PD could be used to reduce M2
macrophages in the tumor microenvironment while
sparing M1 antitumor macrophages.

Materials and Methods
Synthesis and characterization of
αvβ3-targeted-MI3-PD NP
αvβ3-targeted-MI3-PD perfluorocarbon NP were
prepared as previously described and characterized
[38] (see Supplemental Data for further discussion
and Figure 1A). A microfluidized suspension of 20%
(v/v) perfluorooctylbromide (PFOB, Exfluor Inc.,
Round Rock, TX, USA), 2.0% (w/v) of a surfactant comixture, and 1.7% (w/v) glycerin. The surfactant comixture of NP included: 0.15 mol% of αvβ3-PEG2000PE, 4 mol% of the MI3-PD, and the balance was high
purity egg phosphatidylcholine (PC) (Lipoid LLC,
Newark, NJ). The surfactant components were
combined with the PFOB, deionized water, and
glycerin. The mixture was pre-blended (Tissumizer
Mark II, Tekmar, Cincinnati, Ohio, USA) then
homogenized at 20,000 psi for 4 min (M110s,
Microfluidics Inc., Westwood, MA, USA). Control
αvβ3-targeted nanoparticles excluded MI3-PD.
Routine NP characterization revealed: nominal size of
http://www.thno.org
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262 nm, polydispersity of 0.09, and zeta potential of
-20 mV as shown in Figure 1B (Brookhaven
Instruments Co, Holtsville, NY, USA). Transmission
electron microscopy images of this nanoparticle were
previously published [38].

Synthesis of MI3-PD 2-Hydroxyethyl 4'methyl-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4yl)amino)-[1,1'-biphenyl]-3-carboxylate (7jc28,
MI3)
To a solution of 4'-methyl-6-((7-nitrobenzo[c]
[1,2,5]oxadiazol-4-yl)amino)-[1,1'-biphenyl]-3-carboxy
lic acid [39] (400 mg, 1.02 mmol, 1 eq) in anhydrous
DMF (15 mL) was added 2-chloroethanol (76 µL, 1.12
mmol, 1.1 eq) and K2CO3 (211 mg, 1.53 mmol, 1.5 eq).
The reaction mixture was stirred at 80 ºC for 3 h, at
which point TLC indicated the reaction was complete.
The reaction was cooled to room temperature then
carefully acidified with 1M HCl. The mixture was
extracted with ethyl acetate (EtOAc ×2), the organic
layers were combined, washed with water (×3), brine
and then dried over Na2SO4. The residue was
re-suspended in ether, vigorously stirred for 30 min,
then the product was isolated by vacuum filtration to
afford the title compound as a bright red solid (376
mg, 85%): 1H (d6-DMSO) δ 2.26 (s, 3H), 3.75 (m, 2H),
4.35 (m, 2H), 5.00 (br, 1H), 6.25 (d, J = 8.8 Hz, 1H), 7.17
(d, J = 7.2 Hz, 2H), 7.35 (d, J = 7.2 Hz, 2H), 7.70 (d, J =
8.0 Hz, 1H), 8.11 (m, 2H), 8.43 (d, J = 8.8 Hz, 1H), 11.04
(s, 1H); 13C (d6-DMSO) δ 25.8, 64.2, 72.1, 108.0, 128.2,
133.3, 133.5, 134.4, 134.6, 134.7, 137.2, 139.7, 142.2,
142.5, 143.7, 144.4, 148.2, 149.2, 149.5, 170.3.
MI3 was used alone as the “free drug” or
esterified with 1-palmitoyl-2-azelaoyl phosphatidylcholine (fatty acid modified oxidized lipid 16:0-9:0
COOH PC, PAzPC) through a dicyclohexyl carbodiimide (DCC)/4-dimethyl amino pyridine (DMAP)
mediated coupling to produce MI3-PD (Figure 1C, D).
The chemical structure of MI3-PD was characterized
by MS spectrometric analysis (ESI-TOF (positive
mode): m/z [C55H80N5O15P]+ Calculated. 082.22 Da.;
Observed (M+H) 1083 Da.

Characterization of the αvβ3-integring
nonpeptide antagonist
The αvβ3-integrin ligand (αvβ3) was a quinolone
nonpeptide antagonist (Figure 1E) developed by
Bristol-Myers Squibb Medical Imaging (BMSMI, US
patent 6,511,648 and related patents) that was initially
reported and characterized as the 111In-DOTA
conjugate RP748 and cyan 5.5 homologue TA145 [40].
The specificity of the αvβ3-ligand mirrors that of
antibody LM609 as assessed by staining and flow
cytometry, and it has a 15-fold preference for the Mn2+
activated receptor (21 nM) [41]. The ligand has broad
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species cross-reactivity. Dissociation constants of the
mimetic in humans established by BMSMI were: 1)
αvβ3-receptor ELISA (biotin-Vn): <1 nM, 2) αvβ5
whole cell assay: 5.4 ± 1.9 µM, 3) αvβ5-receptor ELISA
(biotin-Vn): 4 nM, 4) α5β1 whole cell assay: > 10 µM,
5) GP IlbIIIa PRP aggregation: > 10 µM, 6) isolated
platelet GP IIbIIIa receptor: 5,289 µM [42]. The
peptidomimetic was coupled via a polyethylene
glycol
spacer
(PEG2000)
to
phosphatidylethanolamine (αvβ3-PEG2000-PE, Gift from Kereos,
Inc, St. Louis, MO). The targeted nanoparticles (NP)
presented ~300 ligands/particle with an IC50 of 50 pM
for the Mn2+-activated αvβ3-integrin [43].

Cell lines
The murine C57BL/6 PyMT-Bo1 luminal B
breast cancer cell line (stably expressing GFP and
firefly luciferase genes) was originally isolated from a
transgenic MMTV-PyMT breast tumor, as previously
validated and described [44]. The PyMT-Bo1 Itbg3
knockout cell line (PyMT-Bo1 β3 KO), was created by
CRISPR genome editing as described below. The 4T1GFP-FL cell line expresses green fluorescent protein
(GFP) and firefly luciferase (FL) and was obtained
from the David Piwnica-Worms lab [45]. The
MDA.MB.435 cell line was obtained from the ATCC.
All cells were maintained at sub-confluence in DMEM
with 10% fetal bovine serum (FBS) and 0.5%
penicillin–streptomycin, in a humidified chamber
under standard culture conditions. Low-passage
stocks were used and regularly tested for
Mycoplasma
and
maintenance
of
growth
characteristics. Primary human umbilical vein
endothelial cells (HUVEC) were obtained from Lonza
(Basel, Switzerland), and express CD31, CD105, von
Williebrand Factor VIII, and were positive for
acetylated low-density lipoprotein uptake. HUVECs
were grown to 70% confluence in VascuLife
Endothelial Cell Culture Media (Lifeline Cell
Technologies, Fredrick, MD, USA) and maintained for
less than five passages.

Generation of an integrin β3 (Itgb3) knockout
breast cancer cell line
PyMT-Bo1 Itbg3 knockout cells (PyMT-Bo1 β3
KO) were generated using the CRISPR/Cas9 system
of genetic engineering. This work was done through
the Genome Engineering and iPSC center (GEiC) at
Washington University School of Medicine (St. Louis,
MO), using the following guide RNAs (gRNAs):
SM903.itgb3.g4: CCTCAACAACGAGGTTATCC
NGG;
SM903.itgb3.g13: CCGGGATAACCTCGTTGTT
GNGG.
Genotyping by targeted deep sequencing of exon
http://www.thno.org
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9 of Itgb3 showed a 25 base pair deletion in one Itgb3
allele and a 31 base pair deletion in the other Itgb3
allele. Flow cytometry analysis of integrin β3
demonstrates the complete loss of surface expression.

Isolation and polarization of bone marrow
macrophages
To generate primary macrophages, whole bone
marrow was extracted from the femurs and tibias of
mice and plated in petri dishes in MEM Alpha media
containing 10% fetal bovine serum and 50 ng/mL
M-CSF. For macrophage polarization assays, day 3
cultured macrophages were plated at 5x105 cells per
well in 6-well cell culture plates and treated for 6-48 h
depending on the assay and polarized with IFN-γ (5
ng/mL) for M1 polarization or IL-4 (5 ng/mL) for M2
polarization or tumor-conditioned media. Tumor
conditioned media was generated from the murine
breast cancer cell line PyMT-Bo1. PyMT-Bo1 cells
were cultured for 24-48 h. Harvested media was
diluted in MEM Alpha macrophage media at a 1:2
ratio and M-CSF was maintained at 50 ng/mL.

In vitro nanoparticle binding assay
Cells treated with 50 pM αvβ3-targeted NP, 50
pM non-targeted NP, or 50 fM of fluorescent 1 µm
carboxylate-modified latex beads (L4655, SigmaAldrich). Cells were incubated for 3 h at the
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appropriate temperature (37 °C or 4 °C) with
continuous shaking. After 3 h, each well was washed
3 times with PBS, and removed with 0.5% trypsin.
Cells were analyzed by flow cytometry analysis on a
BD LSRFortessa (BD Biosciences) and data analysis
was performed with FlowJo software version 10.1
(Tree Star).

RNAseq data acquisition and analysis
RNAseq normalized data were downloaded
from the Gene Expression Omnibus database [46].
Whole-tissue breast cancer RNAseq data were
obtained from the GSE100925 as normalized FPKM
[47]. RNAseq data from breast cancer TAMs (CD45+
CD3/56/19-CD11b+CD14+CD163+) and circulating
monocytes (CD45+, CD3/CD19/CD56-, HLA-DR+)
were downloaded from the GSE117970 dataset as
normalized CPM (described in the original work) [47].
Conversion of gene identifiers between entrez gene ID
and official gene name was run on the Database for
Annotation, Visualization and Integrated Discovery
[48, 49] and verified on the individual gene’s Uniprot
entry. The corresponding gene list is shown in
supplemental Table S1. Prism8 (GraphPad) was used
to generate plots and calculate Pearson’s correlation
coefficient r and p values.

Figure 1. Development of αvβ3 targeted MI3 prodrug perfluorocarbon nanoparticles (PFC). (A) PFC nanoparticles deliver MI3 prodrug through a
contact-facilitated drug delivery mechanism. (B) Analysis of the average PFC nanoparticle diameter, polydispersity and zeta potential (C) MYC/MAX dimerization inhibitor MI3
prodrug (D) MYC inhibitor MI3 (E) αvβ3-integrin targeting ligand.

http://www.thno.org
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Pharmacological inhibition of phagocytosis
For pharmacological inhibition of phagocytosis,
macrophages were pretreated for 1 h with 5 μM of the
phagocytic inhibitor Cytochalasin D (CytoD), (sc201442, Santa Cruz Biotechnology), which inhibits
actin polymerization on the plasma membrane.
Alternatively, macrophages were pre-cooled at 4 °C
for 1h, which also inhibits actin dynamics [50, 51].
After 1 h, cells were then treated with either NP or
latex phagocytic beads, at the appropriate culturing
conditions (in the presence of CytoD, or at 4 °C).

In vitro MI3-PD dosing
Macrophages were cultured for 3 days as
described above. Cells were then trypsinized and
plated onto petri dishes with MEM Alpha media and
50-100 ng/mL M-CSF and polarized with IFNγ (5
ng/mL), IL-4 (5 ng/mL) or tumor-conditioned media
(1:2). The following day, cells were dosed with MI3
prodrug and fresh media containing M-CSF with
cytokines or tumor conditioned media (TuCM). After
48 h cells were assessed by MTT or RNA was
harvested with the RNeasy kit (Qiagen).

MTT viability assay
The MTT viability assay was performed as
described previously [52]. For post-polarization
assays, cytokine (IL-4, IFNγ, TuCM) was added 24 h
prior to the addition of drug or nanoparticle. Prepolarization assays were treated with drug or
nanoparticle 1 h prior to the addition of polarizing
cytokines or tumor conditioned media. Signal
intensity is reported as OD570. Cell viability was
assessed at 6-48 h.

Real-time quantitative PCR (qPCR) analysis
Total RNA from cells was isolated with the
RNeasy Mini Plus kit (Qiagen). Complementary DNA
was made using the (qScript cDNA Synthesis Kit,
Quanta). qPCR was performed using PerfeCTa SYBR
Green FastMix (Quanta), with mouse-specific primers
for mRNA genes of interest: Actin, C-myc, Max,
Akap12, Wnt5a, Maoa, Mrc1, Myc, and Pcsk5, analyzed
using the ∆∆Ct method. The primer sequences are
shown in supplemental Table S2.

Arginase 1 – yellow fluorescent protein (YFP)
assay
Macrophages were isolated from mice
genetically engineered to express the YFP protein
downstream of the endogenous stop codon of the
Arginase 1 gene (Jackson Labs, B6.129S4-Arg1tm1Lky/J)
[53]. Bone marrow macrophages were cultured as
described, plated in MEM Alpha media containing 50
ng/mL M-CSF and 0.5 ng/mL of IL-4. After 24 h of
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polarization, cells were treated with MI3 prodrug for
48 h and Arg1 expression read by YFP expression was
assessed by flow cytometry.

Animals Use
Animal studies were approved by and
performed in accordance with the guidelines
established
by
the
Washington
University
Institutional Animal Care and Use Committee
(IACUC). All mice were obtained from The Jackson
Laboratory and were housed according to the
guidelines of the Division of Comparative Medicine,
Washington University School of Medicine.

Murine cancer models and therapeutic dosing
To establish orthotopic mammary fat pad (MFP)
tumors, 0.1×106 PyMT-Bo1 β3 KO and 4T1-GFP-FL
tumor cells were resuspended in 50 µL PBS and
implanted into MFP tissue of 7-8 week-old female
C57BL/6 mice. MI3-PD encapsulated in αvβ3-NP was
dosed at 4.5 mg/kg per injection with 3 nanoparticle
injections per experiment.

Bioluminescence imaging (BLI) analysis
In vivo BLI was performed on IVIS50
(PerkinElmer, Waltham, MA) as previously described
[44]. Total photon flux (photons/sec) was measured
from fixed regions of interest (ROIs) using Living
Image 2.6. Investigators were blinded to treatment
groups during all BLI analyses.

Flow Cytometry of mammary fat pad tumors
Tumors were harvested, minced and incubated
in 1X collagenase for 1 h at 37 °C shaking.
Collagenased tumor was put through a 70 µm cell
strainer, washed in media, and cell counted. Cells
were prepped for flow cytometry by aliquoting 3
million cells into wells in a 96-well v-bottom plate.
Cells were spun at 12000 RPM for 5 min at 4 °C, media
removed and incubated for 20 min with Fc block.
After FACS Buffer (PBS, 5% FBS, EDTA) wash, cells
were incubated with antibody for 20 min, washed
twice in FACS buffer and resuspended for flow
cytometry on the BD X-20Fortessa. The antibody
panel used for flow cytometry is available in
supplemental Table S3.

Statistical analysis
All data is shown as mean with error bars
representing SEM. All sample sizes reported in the
study are the minimum number of samples. For
animal studies, sample sizes were estimated
according to our previous experience. Statistical
differences were analyzed using either a two-tailed
t-test, ANOVA with Tukey’s test for a posteriori
(post-hoc) multiple comparisons or a two-tailed
http://www.thno.org
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unpaired t-test with Bonferroni correction for a priori
comparisons between a control group and
experimental
treatment
groups
of
interest.
Assumptions for ANOVA and t-test (independent
samples, approximately normal distributions) for
samples n>5 were sufficiently met, or used if a
random sample of n≤5 were selected from an
approximately normally distributed population. Nonnormally distributed data were analyzed using a twotailed Mann–Whitney U-test or a two-tailed Wilcoxon
signed-rank test for matched-pairs. All tests were
considered significant at P≤0.05. Data analyses were
performed with Prism 8 (GraphPad Software).

Results
Integrin β3 is expressed on human breast
cancer-associated macrophages and can be
targeted by nanoparticles in mice
We have previously shown that integrin β3 is
expressed on tumor-infiltrating M2 phenotype
macrophages in mice [44]. To determine whether
integrin β3 is also expressed on breast cancerassociated macrophages, human tissue arrays of nonmalignant and breast cancer tissues were assessed for
infiltration of activated macrophage (CD68+) and
expression of integrin β3 (CD61+). We found that the
percent of CD68+ macrophages was significantly
increased in human breast cancer compared to normal
tissue. Further, 64% of CD68+ TAMs also expressed
integrin β3 in breast cancer tissue as compared to 20%
in normal breast tissue, indicating the potential to
target these cells with αvβ3-NP-mediated drug
delivery (Figure 2A).
Surface integrin β3 expression was evaluated by
flow cytometry on tumor and endothelial cell lines
using antibodies against murine integrin β3 (CD61) or
activated human αvβ3 (LM609). As previously
published, high levels of activated human αvβ3 were
observed in MDA.MB.435 melanoma cells and
HUVEC endothelial cells as indicated by the mean
fluorescence intensity (MFI) of 42 and 27 respectively
(Figure 2B). Integrin β3 expression was also observed
in the murine estrogen receptor positive (ER+) breast
cancer cell line PyMT-Bo1 but at relatively lower
levels (17 MFI, Figure 2B). In vitro binding of αvβ3-NP
labeled with rhodamine (αvβ3-rhodamine NP)
revealed αvβ3-rhodamine NP uptake was similar to
the amount of surface integrin expression observed by
flow cytometry (CD61 or LM609, Figure 2B).
We have previously shown that αvβ3-NP bind
to the tumor endothelium in vivo [54]. We next
assessed the ability of αvβ3-rhodamine NP to bind
myeloid cells in vivo. Non-tumor bearing mice were
injected with αvβ3-rhodamine NP or PBS. Bone
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marrow was harvested and analyzed by flow
cytometry for myeloid cell marker CD11b and
rhodamine fluorescence 3 h after inoculation.
Rhodamine-positive CD11b+ cells were not detected
in PBS treated mice (<1%) but were present in mice
injected with 50 µl or 100 µl αvβ3-NP. Rhodamine+,
CD11b+ bone marrow cells correlated with the
amount of αvβ3-NP injected at 35% and 49%
respectively (Figure 2C). These data indicate αvβ3targeted nanoparticles can bind to a significant
number of CD11b-expressing myeloid cells in bone
marrow in vivo.

Integrin αvβ3-targeted nanoparticles can
deliver rhodamine payload to M2
macrophages in part through a
phagocytosis-independent mechanism
Next, we assessed integrin β3 expression on in
vitro cultured bone marrow macrophage populations
(BMMs): unpolarized macrophages (M0, M-CSF
alone), M1 (classically polarized using M-CSF+IFNγ),
M2 (alternatively polarized using M-CSF+IL-4). By
flow cytometry, integrin β3 expression was increased
14-fold in M2 macrophages as compared to
expression in M1 macrophages and 7-fold as
compared to M0 macrophages (381, 27 and 57 MFI
respectively, Figure 3A). To confirm that the αvβ3
targeting ligand used in these nanoparticles bind to
M2 macrophages, we used an activated αvβ3 specific
targeting ligand conjugated to a fluorescence probe
and incubated with bone marrow macrophages
isolated from WT or β3 deficient mice [55]. The αvβ3
targeting probe showed a non-specific 4-fold increase
in binding to β3 KO M2 macrophages compared to the
unstained control while the binding was increased
12-fold in WT M2 macrophages (Figure S1). We next
incubated bone marrow derived macrophages with
αvβ3-rhodamine NP and found that greater than 70%
of cells in all three subsets of macrophages (M0, M1
and M2) were rhodamine positive.
Typically, phagocytosis refers to the engulfment
of particles of 500 nm of diameter or larger, achieved
through reorganization of the actin cytoskeleton and
lipid membrane. In professional phagocytic cells such
as macrophages, this follows the activation of specific
receptors, such as FcR. Macrophages can phagocytose
polymeric particles, requiring strategies to prevent
lysosomal degradation of cargo drugs. To assess
whether αvβ3-rhodamine NP were taken up
exclusively by phagocytosis or a non-phagocytic
mechanism like contact facilitated drug delivery
CFDD (Figure 3B) [37, 56-59], we evaluated uptake in
the presence of phagocytosis inhibitors.

http://www.thno.org
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Figure 2. Human breast cancer tumor-associated macrophages express β3 integrin. (A) Immunofluorescence of CD68+ (n=10, n=108) and CD68+, CD61+ (n=10,
n=106) macrophages in human non-malignant (blue) and malignant breast tissue (red), respectively (***P≤0.001). (B) Flow cytometry analysis of β3 integrin expression (blue) and
nanoparticle uptake (rhodamine+) by murine breast cancer cell line (PyMT-Bo1, MFI 17), human melanoma (MDA.MB.435, MFI 27) and human endothelial (HUVEC, MFI 42) cell
lines in vitro. Duplicate biologic replicates were preformed with representative images shown. (C) Flow cytometry analysis of bone marrow from PBS or αvβ3-rhodamine treated
mice (n=3). MFI: median fluorescent intensity.

Cytochalasin D inhibits phagocytosis and
macropinocytosis by disrupting actin polymerization.
There was a marked cell number reduction in
rhodamine uptake after incubation with αvβ3rhodamine NP and cytochalasin D in the M1
macrophages of 4% and in the M0 macrophages of
13%; whereas, rhodamine cellular uptake by 50% was
noted after incubation with αvβ3-rhodamine NP and
cytochalasin D in the M2 macrophages (Figure 3C).
These data suggest that M0, M1 and M2 macrophages
can phagocytose αvβ3-rhodamine NP, however, of
the macrophage subsets evaluated, the M2
macrophages, which have the highest αvβ3
expression, have the greatest ability to take up cargo

through a phagocytosis-independent mechanism.

MI3 prodrug reduces expression of MYC
regulated genes with known roles in
macrophages polarity
MYC is an oncogene frequently expressed in
cancer cells. MYC expression has more recently been
reported in tumor-associated macrophages (TAMs)
[60]. To determine whether our targets MYC and
MAX were expressed by macrophages in human
breast cancer, publicly available RNAseq data sets on
human breast cancer TAMs [47] were analyzed for
MYC and MAX levels. MYC and MAX RNA were
detected in circulating breast cancer monocytes
http://www.thno.org
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(KRT7+, CD11b+, CSF1R+), whole breast cancer tissue
(KRT7+, CD11b+, CSF1R+), and isolated breast cancer
tumor infiltrating macrophages (KRT7 negative or
low, CD11b+, CSF1R+), supporting a potential role for
MYC in human TAMs (Figure 4A). Evaluation of
murine BMM also demonstrated that Myc expression
was upregulated upon IL-4-induced M2 polarization
when normalized to M0 mRNA, whereas Myc
expression was decreased by IFNγ-induced M1
polarization. Collectively, we found that M2 polarized
BMMs (IL-4-induced, or tumor conditioned media
induced) had increased expression of Myc mRNA as
compared to M0 or IFNγ-induced M1 macrophages
(Figure 4B).
To test the ability of our MYC-MAX
dimerization inhibitor MI3 prodrug (MI3-PD) to
reduce expression of known MYC-regulated genes
involved in M2 polarization, mRNA expression of
MI3-PD treated BMMs was assessed [60]. MYC
inhibition of early macrophages prior to IL-4-induced
M2 polarization decreased known MYC regulated
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genes, including the M2 markers Maoa and CD206
(Mrc1) (Figure 4C). MI3-PD inhibition of more
established M2 macrophages (after IL-4 polarization)
significantly decreased expression of an alternative
set of MYC regulated genes, including Akap12 and
Wnt5a. MI3-PD had no effect on expression of Myc or
Pcsk5, a gene regulated independent of MYC (Figure
4D) [60]. Finally, macrophages were polarized using
breast cancer tumor-conditioned media (TuCM) to
evaluate the effects of MYC inhibition on
macrophages in a breast cancer context. MYC
inhibition of BMM polarization with TuCM decreased
Akap12 and Wnt5a, an effect similar to what we
observed in IL-4-polarized M2 macrophages treated
with MI3-PD (Figure 4E).
We next assessed the ability of MI3-PD to reduce
protein expression of well-known M2 polarity marker
Arginase I (ARG1). The transgenic B6.129S4Arg1tm1Lky/J mice (ARG1-YFP) express yellow
fluorescent protein (YFP) downstream of the Arg1
gene, reporting in vivo on the level of ARG1

Figure 3. Nanoparticle delivery of MI3 prodrug occurs in part through a non-phagocytic mechanism in M2 macrophages. (A) Flow cytometry analysis for β3
integrin expression and the percent of cells positive for rhodamine following in vitro incubation with αvβ3 rhodamine labeled nanoparticles (NP) in M0 (blue, MFI 57), M1 (green,
MFI 27) and M2 (purple, MFI 381) macrophage subsets. (B) Nanoparticles can deliver drug through a contact-mediated drug delivery mechanism or non-specific phagocytosis.
Contact-facilitated drug delivery avoids sequestration and degradation in the endocytic pathway. (C) Flow cytometry analysis of the percent of cells positive for rhodamine in the
presence (orange) or absence (blue) of phagocytosis inhibitor Cytochalasin D after in vitro incubation with αvβ3-rhodamine labeled nanoparticles as compared to vehicle treated
controls (red). Representative experiments are shown. Biologic replicates were completed in triplicate for all experiments.
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biosynthesis. To validate in live cells the effect of MYC
inhibition, BMM were isolated from ARG1-YFP,
cultured and polarized with TuCM in vitro, and then
treated with MI3-PD [53]. MI3-PD inhibition reduced
arginase expression by 35%, compared to vehicle
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treated M2 BMMs (Figure 4F). Interestingly, MI3-PD
had no effect on macrophage viability in TuCM
polarized macrophages, or IFNγ-polarized M1
macrophages in vitro (Figure 4G).

Figure 4. MI3 prodrug treatment reduced expression of MYC regulated genes involved in alternative activation of M2 macrophages. (A) Quantification of
MYC and MAX expression in human breast cancer tissues from by RNAseq analysis. (B) qPCR of Myc mRNA expression in murine bone marrow macrophage subsets M0, M1
(IFNγ), M2 (IL-4) and tumor conditioned media (TuCM) polarized macrophages (6 h). Quantitative PCR of known MYC regulated genes in (C) M0 macrophages treated with IL-4
and MI3 prodrug (MI3-PD, 6 h), (D) established IL-4 M2 macrophages and (E) established tumor TuCM polarized macrophages treated with MI3-PD (24 h) post polarization. (F)
Flow cytometry of Arg1-YFP reporter macrophages polarized with TuCM and treated with MI3-PD (48 h). (G) MTT viability assay for macrophages treated with MI3-PD (48 h).
Data shown is the average of two biologic replicates. (H) Correlation of CD47 and MYC expression in human breast cancer by in silico analysis of RNAseq data sets. (I) RNAseq
data from murine breast cancer TAMs (DAPI−CD45+CD11b+Ly6G−Ly6C−F4/80+, GSE104765, n=12) was assessed and normalized values as presented in the original paper, were
tested for correlation. (J) Cd47 qPCR of murine M2 (IL-4) macrophages treated with MI3-PD (24 h). All qPCR experiments were shown as representative experiments and 2-3
biologic replicates were performed for each. P-values are denoted as follows: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001. ND: not detectable, ns: not significant.
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Figure 5. αvβ3-targeted MYC inhibitor MI3 loaded nanoparticles decreased M2 tumor-associated macrophages in the 4T1-GFP-FL (4T1) murine breast
cancer model. (A) 4T1 cells were implanted into the mammary fat pad (MFP, day 0) and mice were given three doses of PBS or αvβ3-MI3-PD nanoparticles (NP, n=6/group).
(B) Bioluminescence imaging (BLI) of in vivo tumor growth (*P≤0.05) (C) Tumor weight at study endpoint (day 16, n=5 mice/group). Flow Cytometry of (D) GFP+ tumor cells,
(E) Tumor-associated macrophages (TAMs) per CD45+ cells and (F) M2-like and M1-like macrophages per total TAMs, isolated from MFP tumors at day 16 (n=5/group,
*P≤0.05). (G) Mouse weight during treatment. (H) Complete blood counts at study endpoint. NP: nanoparticle; WBC: white blood cell; ns: not significant.

CD47 is a key receptor necessary for cells to
avoid the immune system, often referred to as the
“don’t eat me” signal. Recent work has shown that
MYC can regulate CD47 expression in tumor cells,
and that anti-CD47 antibody treatment of tumors
increases the number of M1 macrophages in the
tumor microenvironment [61, 62]. We found through
in silico assessment of RNAseq data sets that CD47
expression correlated with MYC expression in human
breast cancer circulating monocytes, whole breast
tumors, human breast cancer TAMs [47], and mouse
mammary fat pad tumor TAMs [63] (Figure 4H,I).
Notably, treatment of M2 macrophages with MI3-PD
significantly reduced CD47 expression as compared to
vehicle treated cells (Figure 4J). Taken together, these
data show that MI3-PD treatment reduced expression
of MYC-regulated genes in protumor M2
macrophages in vitro.

Integrin αvβ3-targeted MI3-PD nanoparticles
reduce mammary fat pad tumor-associated
macrophages in vivo
When applied systemically, MYC inhibitors are
quickly degraded in blood, leading to reduced drug
bioavailability [36, 64]. Encapsulation within
nanoparticles could increase efficacy by enhancing
stability in circulation, increasing the amount of drug
membrane payload delivered directly to target cells,
and reducing off-target effects and toxicity. To
evaluate whether αvβ3-MI3 PD nanoparticles were
effective in vivo, mice bearing mammary fat pad
(MFP) tumors were established, using an aggressive
triple-negative murine breast cancer line 4T1-GFP-FL
(BALB/C) that expresses integrin αvβ3 (Figure S2).
Mice were given three doses of PBS or αvβ3-MI3-PD
NP and tumors were evaluated by flow cytometry at
http://www.thno.org
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study endpoint. Early stage tumors were assessed due
to the large number of TAMs and the presence of both
M1 and M2 macrophage subsets, compared to later
stage tumors where M2 subsets predominate. We first
assessed the effect of αvβ3-MI3-PD NP treatment on
tumor growth by bioluminescent imaging (BLI) and
tumor weight. Tumor growth at the early time point
as measured by BLI (Figure 5B) and tumor weight at
endpoint (Figure 5C) was similar between PBS and
αvβ3-MI3-PD NP treatment groups. Following
collagenase digestion, tumor composition was
evaluated by flow cytometry. Analysis of tumor cells
(GFP) showed there was no significant difference
between control and treatment groups (Figure 5D).
The percent of tumor-associated macrophages (TAMs:
CD45+, CD11b+, GR1-, F4/80+) per total CD45+ cells
within the MFP tumors was similar between
treatment groups (Figure 5E). However, the percent of
protumor M2 TAMs (CD45+, CD11b+, GR1-, F4/80+,
MHCII low, CD206 high) was significantly decreased
(14%) in αvβ3-MI3-PD NP treated mice, as compared
to PBS (Figure 5F). Moreover, the percentage of
antitumor M1 TAMs (CD45, CD11b, GR1-, F4/80+,
MHCII high, CD206 low) was significantly increased
(14%) in MFP tumors of αvβ3-MI3-PD NP compared
to PBS treated mice (Figure 5F, Figure S3). For toxicity
assessment, there were no differences between groups
in the percent change in body weight, and for
complete blood counts (CBC), including white blood
cells, neutrophils, and platelets (Figure 5G,H). These
data suggest that αvβ3-MI3-PD NP changed the
composition of breast cancer tumor-associated
macrophages, biasing towards low M2 TAMs, while
inducing little systemic toxicity.

αvβ3-MI3-PD nanoparticles do not directly
target tumor cells to decrease M2
macrophages in breast tumors
The reduction in M2 macrophages in our 4T1
breast tumors treated with αvβ3-MI3-PD NP could be
explained, theoretically, either by direct effects on
αvβ3+ macrophages by MI3, as shown in vitro, or by
indirect effects of MYC inhibition in the αvβ3+ 4T1
cancer cells. In addition the 4T1 model has a lower
M2/M1 ratio compared to the PyMT breast cancer
models, which could underestimate the effect of M2
targeted agents. Therefore, we next evaluated αvβ3
directed MI3-PD NP therapy in a second breast cancer
model, PyMT Bo1, which we engineered to lack
tumoral β3. We selected PyMT-Bo1, which is a
C57B/6 syngeneic ER+ luminal B type breast cancer
cell line that expresses αvβ3 in vivo (Figure 6A) and
has a higher M2/M1 ratio than 4T1 cells in vivo. We
used the CRISPR/Cas9 system to genetically disrupt
β3 expression (Figure 6B) and established PyMT-Bo1
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β3 knockout (KO) MFP tumors and treated with the
same dosing strategy as the 4T1 model (Figure 6C).
We selected an ER+ luminal B type breast cancer cell
line PyMT-Bo1 as a second immunocompetent breast
cancer model. Although PyMT-Bo1 cells express
relatively low levels of β3 integrin compared to
endothelial cells (Figure 2B), we have observed
upregulation of β3 expression in vivo (Figure 6A,
Figure S4A) and therefore used the CRISPR/Cas9
system to genetically disrupt β3 expression (Figure
6B). We established PyMT-Bo1 β3 knockout (KO)
MFP tumors and treated with the same dosing
strategy as the 4T1 model (Figure 6C). To demonstrate
that macrophage effects were specific to
MI3-PD-mediated MYC inhibition, rather than due to
non-specific nanoparticle-binding effects, mice were
treated with PBS, drug-free αvβ3-NP, or αvβ3-MI3PD NP. In this experiment, bioluminescent imaging
(BLI) was used to assess the presence of cancer cells
expressing firefly luciferase, as opposed to nonluciferase expressing host cells, within the tumor. By
this measure, tumor burden significantly decreased
with αvβ3-MI3-PD NP therapy, as compared to PBS
or αvβ3-NP treated control groups (Figure 6D).
Tumor weight was not changed between treatment
groups (Figure 6E). The similar tumor size could be
due to an influx of immune or other cell types within
the αvβ3-MI3 NP treated tumor or because tumors
were harvested at early stages.
We further evaluated tumor composition by
flow cytometry and found no significant difference in
the number of tumor cells as a percent of total cell
number (Figure 6F). As with the 4T1 experiments, the
overall number of TAMs (CD45+, CD11b+, GR1-,
F4/80+) per CD45+ cells was not different between
treatment groups (Figure 6G), but the composition of
macrophage subsets were. There was a significant
decrease (18%) in the percent of M2 TAMs (CD45+,
CD11b+, GR1-, F4/80+, MHCII low, β3 integrin high)
and a significant increase (16%) in the percent of M1
TAMs (CD45+, CD11b+, GR1-, F4/80+, MHCII high,
β3 integrin low) with αvβ3-MI3-PD NP therapy
(Figure 6H, Figure S4B). There was no change in M2
and M1 ratios in the PBS and αvβ3-NP control groups,
indicating this effect was not due to the nanoparticle
components or the targeting ligand (Figure 6H).
Further, there was no change in MDSC or T cell
populations with αvβ3-MI3-PD NP treatment (Figure
S5). The toxicity assessments of percent change in
mouse weight and blood counts, circulating
neutrophils, white blood cells, or platelets remained
the same between treatment groups αvβ3-MI3-PD NP
treatment, as compared to the controls (Figure 6I, J).
To evaluate whether non-targeted MI3-PD
nanoparticles (MI3-PD NP) could reduce tumor
http://www.thno.org
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burden, we treated mice with PyMT-Bo1 β3 KO MFP
tumors with PBS, MI3-PD NP or αvβ3-MI3-PD NP.
Tumor burden was reduced (P<0.05) in the targeted
MI3-PD nanoparticle group but not decreased
(P>0.05) with non-targeted MI3-PD NP, suggesting
the reduction in tumor burden as assessed by
luciferase expression in tumor cells was a result of
targeted delivery of MI3 prodrug (Figure 6K). Tumor
weight was unchanged between treatment groups
similar to our prior results in the 4T1 and PyMT
experiments (Figure 6L). Tumor weight is comprised
of a dynamically changing mixture of inflammatory
cells, edema, fibrosis, and necrosis as well as
malignant cells, which themselves occupy only a
fraction of the volume [65]. Together, these data
suggest that down modulation of protumor M2
macrophages by αvβ3-MI3-PD NP decreased (P<0.05)
tumor activity in both an ER+ a triple negative breast
cancer model two mouse genetic backgrounds
without any hematological toxicity.

Discussion
Tumor-associated
macrophages
(TAMs)
promote tumor growth and metastasis while also
reducing the effectiveness of chemotherapy and
immunotherapy. We and others have shown that
murine protumor M2 macrophages have increased
MYC and integrin αvβ3 expression. We reported that
integrin αvβ3-expressing M2 macrophages promote
breast cancer tumor growth in preclinical models [44],
so we proposed a two-step therapeutic approach
using a small molecule inhibitor to MYC-MAX by a
vitronectin peptidomimetic targeting antagonist to
the activated form of integrin αvβ3. We show for the
first time that TAMs from human patient breast
cancers express integrin αvβ3 and they also express
MYC. Although MYC is an important target in tumor
cells, MYC has not been therapeutically targeted in
tumor-associated macrophages in vivo. We found that
MYC inhibitor MI3, delivered through αvβ3-targeted
NP, reduced M2 macrophages while preserving
beneficial M1 macrophages in vivo. These effects were
observed in two mouse models of ER+ and triple
negative breast cancer in two animal backgrounds.
MYC is expressed in human and mouse macrophages
cultured in vitro, but MYC expression in breast cancer
TAMs has not been explored. TAM populations often
consist of a mixture of tissue resident macrophages
and recruited monocytes. By RNAseq analysis of
published data sets, we found that circulating
monocytes and tumor-associated macrophages from
breast cancer patients express MYC. Macrophages
cultured
in
tumor
conditioned-media
also
upregulated Myc, at similar levels to those induced
during M2-polarization by IL-4. These data provide
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new support for the role of MYC in breast cancer
TAMs, and highlight the therapeutic potential of
targeted drug delivery against protumor M2 TAMs.
Interestingly, MYC expression in tumor cells also
promotes breast cancer progression, indicating that
anti-MYC therapy could have compounding
antitumor benefits, which are currently under
investigation.
MYC can act as an amplifier of multiple
signaling pathways, regulating the expression of a
number of genes, which can be used as a functional
marker for MYC/MAX activity. Treatment of murine
peritoneal macrophages and human monocytes with
MYC/MAX inhibitor 10058-F4 (MI1) in vitro
decreased genes known to be involved in alternative
M2 polarization [60]. Some studies have suggested
that the differences in the tissue origin of TAMs
populations may result in different functions while
others, indicate microenvironmental cues educate
these TAMs towards a similar phenotype [66]. We
therefore investigated the role of MYC in bone
marrow macrophages (BMM), polarized towards an
M2 phenotype with IL-4 or with media conditioned
by a breast cancer cell line. We found that treatment of
BMM with MI3 prodrug, which has a longer
intracellular half-life than previous MYC inhibitor
MI1 [39, 67], inhibited a similar set of genes important
in M2 polarization (Maoa, Akap12, Wnt5a, and Mrc1).
Moreover, we show new data indicating that the
timing of MYC inhibition relative to addition of the
polarizing stimulus can affect the transcription of
different sets of MYC target genes. Downregulation of
the key markers of M2 polarization, Cd206 and
arginase 1, suggests that nanoparticle-mediated drug
delivery of MI3 MYC inhibitors could reduce M2
macrophage polarization and function in vivo [68].
Furthermore, we found that MYC inhibition can
decrease Cd47 in tumor-associated macrophages in
vitro. CD47 has emerged as an important checkpoint
for the immune system [69]. Tumor cells upregulate
CD47, known as the “don’t eat me” signal, to escape
recognition and clearance by immune cells including
macrophages. MYC has been shown to regulate CD47
expression in some tumor types [61]. Inhibition of
CD47 on tumor cells promotes M1 macrophages in
the tumor microenvironment, although it is unclear
whether this occurs through increased recruitment of
M1 macrophages or reprogramming of existing
macrophages toward an M1 phenotype [62]. We also
found that MYC expression correlates with CD47
expression in human whole breast tumor tissue,
circulating
monocytes,
and
tumor-associated
monocytes in patients with breast cancer, indicating
that MYC regulation of CD47 may be conserved
within breast cancer TAMs as well. We hypothesize
http://www.thno.org
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that MYC downregulation of Cd47 may contribute to
the M1/M2 shift in our models of breast cancer.
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Additional work will be needed to investigate this
mechanism.

Figure 6. MYC inhibitor MI3 reduces pro-tumoral M2-like macrophages and enhances M1-like macrophages in an in vivo breast cancer model. (A) Integrin
β3 expression on PyMT-Bo1 tumor cells isolated from breast cancer metastases in bone. (B) Flow cytometry of β3 expression (orange) (C) β3 KO cells were implanted into the
mammary fat pad (MFP) of mice that were treated with PBS, no drug αvβ3-nanoparticles (NP) or αvβ3-MI3 prodrug nanoparticles (αvβ3-MI3-PD NP, n=4/group). (D)
Bioluminescence imaging (BLI) of in vivo tumor growth (*P≤0.05). (E) Tumor weight at day 16. Flow cytometry analysis of (F) GFP+ tumor cells (G) Tumor associated
macrophages (TAMs: CD45+, CD11b+, Gr1-, F4/80+) per CD45+ cells and (H) M2-like (MHCII low, β3 integrin high) and M1-like macrophages (MHCII high, β3 integrin low)
per TAMs (n=2-3 mice/group) in day 16 MFP tumors. (I) Mouse weight during treatment. (J) Complete blood counts at study endpoint (n=3-4/group). (K) BLI of in vivo tumor
burden (n=5/group). (L) Tumor weight at day 15. *P≤0.05, **P≤0.01, ns: not significant; WBC: white blood cell.
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Direct
macrophage
targeting
with
nanotechnologies, has focused on exploitation of the
surface macrophage activation markers CD44 and
CD206, which have a higher expression on M2 but are
also expressed on M1-type cells [70-73]. Our group
has previously shown that integrin αvβ3 is not
expressed at high levels on unpolarized myeloid cells
or M1 macrophages, but is upregulated on M2
macrophages; furthermore, we found that integrin β3
plays a functional role in maintaining macrophage
homeostasis and serves as a negative inhibitor for M2
function [44]. Here, we show that integrin β3 is
expressed on the majority of TAMs in human breast
cancer patient tissues and we use αvβ3-targeted
nanoparticle technology to deliver our MI3 prodrug in
vivo.
To demonstrate NP targeting of MYC in M2
macrophages while preserving M1 macrophages, we
evaluated the effects of our NPs using small early
stage tumors, which in our hands, have a large
immune component including both M1 and M2
macrophages. We found that αvβ3-MI3-NP
significantly decreased M2 macrophages and
increased M1 macrophage numbers in two breast
cancer models. Tumor weight was not changed at the
time of analysis although changes in bioluminescent
activity were observed. We demonstrated a significant
decrease in tumor burden by BLI with αvβ3-MI3-PD
treatment. This reduction was not present in the
αvβ3-NP or MI3-PD nanoparticles control groups.
There are several challenges to evaluating tumor
burden as tumor weight may not reflect changes in
the cellular composition of a tumor. Bioluminescence
imaging represents tumor activity in vivo without
mechanical tissue disruption and may be a better
reflection of real time tumoral changes; however BLI
depends on ATP, oxygen and luciferin availability.
Interestingly, there is clinical evidence that immune
therapies often change the tumor cellular composition
and metabolic uptake as measured by FDG PET,
before eventually reducing tumor size [74]. Radiology
societies have modified the criteria for evaluating
treatment response in solid tumors to account for
unchanged or pseudo-progression of tumor volumes
due to the influx of inflammatory cells [75]. Clinical
studies have shown that immune checkpoint
inhibitors are less effective in some breast cancer
subtypes like ER+ cancers. It is thought that
macrophages play a large functional role in immune
suppression in breast cancer. Clinical testing of
generalized macrophage inhibitors are underway but
there are concerns for inhibiting anti-tumor M1
phenotype macrophages as well. Our data suggest
that patients with higher levels of TAMs could derive
more benefit from immune checkpoint therapies
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when combined with macrophage-targeted therapies
such as αvβ3-MI3-PD NP. It is possible that
αvβ3-MI3-PD NPs had less impact on tumor cell
burden as measured by BLI in the 4T1 triple negative
breast cancer compared with the ER+ PyMT-Bo1
breast cancer, because there are significantly lower
percent of M2-type TAMs in the 4T1 model as
compared to the PyMT-Bo1 control tumors.
In macrophages, activation of specific receptors
is required for phagocytosis and includes opsonin,
scavenger and toll like receptors, among others [76].
Receptor expression can be specific to macrophage
subtype and determines the type of particles (bacteria,
parasites, cell debris) phagocytosed [77, 78]. Uptake of
diverse particles by specific receptors, suggests M1
and M2 macrophages could use different internal
mechanisms to process phagocytic particles and
differences in phagosome maturation (ie. pH changes
and pathway kinetics). Recent work has shown M2
macrophages may have increased phagosome
maturation [79], however; for the purpose of this
work, we did not explore downstream processes but
instead used a broad microtubule inhibitor
(Cytochalasin D) to block actin polymerization
dependent phagocytosis and macropinocytosis.
Control studies using agarose beads showed complete
inhibition of bead uptake in M2 macrophages
following CytoD treatment indicating CytoD
concentrations were sufficient to block phagocytosis.
Some studies have shown inhibitors can affect other
endocytic pathways and we cannot rule out inhibition
of clatherin-mediated endocytosis in addition to
phagocytosis. However, several papers have
demonstrated that CytoD treatment in macrophages,
completely inhibit phagocytosis, but does not affect
other endocytic pathways [80-82]. These data in
combination with our in vivo reduction of M2
macrophages suggests αvβ3 targeted NP can deliver
drug to M2 macrophages that avoids degradation in
the phagocytic pathway, resulting in more efficacious
concentrations of drug in the cytosol.
A key finding of this work was the observation
that integrin β3 is expressed on human breast cancer
tumor-associated macrophages. In this paper we used
tumor cell lines expressing β3 or β3 KO tumor cell
lines to examine the effects of αvβ3-MI3-PD
nanotherapy on β3-expressing macrophages. Because
triple-negative breast cancers express elevated levels
of MYC, we speculate that future studies developing
similar tumor cell lines may help explore this dual
targeting strategy in this group of patients, who have
limited options for targeted therapies.
Many other cell types in the tumor
microenvironment express αvβ3 integrin including:
tumor induced angiogenic cells, bone-residing
http://www.thno.org

Theranostics 2020, Vol. 10, Issue 17
osteoclasts, immune cells, and some types of tumor
cells which could be targeted by the αvβ3-MI3-PD NP
[83].
However,
the
integrin
αvβ3-targeting
peptidomimetic binds with high affinity to the ligandbinding domain exposed with activated integrins,
avoiding binding to inactivated αvβ3 integrin on
quiescent cells. We have previously shown that
integrin αvβ3-targeting to the neovasculature can be
used to specifically deliver cargoes with αvβ3-PFC NP
in pathologic animal models of cardiovascular,
inflammatory disease and cancer [54, 84, 85]. The
cMYC-MAX pathway is upregulated in tumor
neovasculature, which also expresses the activated
integrin [86]. αvβ3-fumagillin NP target targeting
neovascular endothelial induce apoptosis releasing
nitric oxide that can suppress macrophage
inflammatory responses [84]. Importantly, αvβ3 is
only expressed on newly forming blood vessels and
not the established tumor vasculature. Thus, the
positive anti-tumor response observed with αvβ3MI3-PD NP may reflect a complicated anti-tumor
response.
Our data show that cMYC-MAX is an opportune
therapeutic target for manipulating the TAM
population
away
from
tumor-promoting
macrophages and that a small molecule antagonist,
modified into a phosphatidylcholine prodrug,
protected the compound from metabolism during
circulation and allowed a unique αvβ3 NP delivery
mechanism (CFDD) to circumvent enzymatic
degradation within the phagocytosis pathway and
discharge directly into the intracellular membranes.
Future research will need to refine and optimize this
concept
with
a
focus
on
corroborative
immunohistological analysis, longer treatment
courses, treatment of larger tumors, and evaluation in
metastatic models. Additionally, the further use of
CRISPR/Cas9 to disrupt integrin β3 expression in 4T1
breast cancer line could establish a useful breast
cancer model to further evaluate whether αvβ3-MI3PD NPs are effective against tumor cells in vivo, and
the use of a smaller 20nm nanoparticle, similar to that
we reported in multiple myeloma models [67], may
enhance
tumor
penetration
and
effective
extravasation. Finally, we propose to investigate
whether macrophage repolarization using αvβ3-MI3PD NPs can enhance responses to immune checkpoint
inhibitors in breast cancer models.
In summary, this research demonstrates the
potential of MYC-MAX inhibition with a small
molecule to affect specific changes in the tumor
promoting M2 macrophage population. A free small
molecule inhibitor known to have poor stability in
circulation was modified into a lipid prodrug and
incorporated into the phospholipid surfactant of
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targeted perfluorocarbon nanoparticles. MYC
inhibition in vitro decreased markers of M2
polarization while αvβ3-mediated drug delivery of
the MYC inhibitor MI3-PD, decreased numbers of M2
TAMs without decreasing M1 macrophages in mouse
models of ER+ and triple-negative breast cancer.
Moreover, BLI of these breast cancer models
demonstrated significant reductions in tumor cells
following αvβ3-MI3-PD NP treatment. The
overarching conclusion of this research is that cMYCMAX inhibition is an important mechanistic target for
anti-tumor treatment, particularly regarding the TAM
population relative polarization, which is enabled by
αvβ3-targeted nanotherapy.
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macrophage monocyte phagocytic system; MTT:
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; NP: nanoparticle; PBS: phosphate buffered
saline; PD: prodrug; PFC: perfluorocarbon; RPM:
revolutions per minute; SEM: standard error of the
mean; TAM: tumor-associated macrophages; TuCM:
tumor conditioned media; αvβ3: integrin heterodimer
of subunits αv and β3; αvβ3-NP: αvβ3 targeted
nanoparticles.
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